For me a VERY solid result, pulling the right leavers , and modest almost breakeven management of cash backed up by a strong balance sheet. Highlights I thought- - Very strong growth in established markets underpinned by an expanding footprint and exponential growth in new markets - Continuing strong margins being responsibly managed with modest price increases to recover costs and ensure future funding and growth. - New manufacturing on stream to underpin future growth and responsibly strengthened admin finance legal HR capacity to allow for globalisation and growth. - Continued investment in frontline future growth initiatives. - Existing initiatives with Barda and DB ulcers remain in budget and on track and further work being done on approvals in China and Japan. Only thing missing for me was New Products initiative beyond repurposing the existing product into new areas of patient care. David indicated we will see other executives at the AGM so hope that’s part of the presentation. I remain a VERY HAPPY LT holder.
PNV Price at posting:
$1.48 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)